Taysha Gene Therapies (TSHA) Share-based Compensation (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Share-based Compensation data on file, last reported at $28.1 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 753.07% year-over-year to $28.1 million; the trailing twelve-month figure through Mar 2026 stood at $28.1 million (up 112.89% YoY), and the FY2025 full-year result was $13.3 million, down 14.21% from the prior year.
• Share-based Compensation rose to $28.1 million in Q1 2026, from $3.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $28.1 million in Q1 2026 to a low of $1.7 million in Q1 2023.
• A 5-year average of $4.7 million and a median of $3.3 million in 2025 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation slumped 68.57% in 2023 and jumped 753.07% in 2026, its largest moves.
• Tracing TSHA's Share-based Compensation over 5 years: stood at $4.1 million in 2022, then slumped by 52.04% to $2.0 million in 2023, then surged by 63.41% to $3.2 million in 2024, then grew by 9.73% to $3.5 million in 2025, then soared by 696.26% to $28.1 million in 2026.
• Business Quant data shows TSHA's Share-based Compensation at $28.1 million in Q1 2026, $3.5 million in Q4 2025, and $3.3 million in Q3 2025.